ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare Inventory Discipline Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCHHHYPOTHETICAL MODEL
Since ’99
−26%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Apr 2021
placeholder
Full Sharpe
-0.01
Ann. Return (LS)
-0.1%
Ann. Volatility
13.9%
Max Drawdown
-52.3%
Test Sharpe ’19–26
-0.13
Test FF5 α (ann.)
0.1%
vs Fama-French 5
Test FF5 α t-stat
0.02
not significant
Monthly turnover
14%
of the long leg, per rebalance
Cumulative return (LS)
-26%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.70
what this fund holds
Long leg ann. return
10.7%
buyable, long-only
Long-short Sharpe
-0.01
requires shorting
Bottom bucket ann. return
10.9%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1UNH
UNITEDHEALTH GROUP INCHealthcare$386.95B
24.56%
2AMGN
AMGEN INCHealthcare$197.69B
12.55%
3DHR
DANAHER CORPHealthcare$144.26B
9.16%
4PFE
PFIZER INCHealthcare$142.77B
9.06%
5HCA
HCA HEALTHCARE INCHealthcare$82.34B
5.23%
6CI
CIGNA GROUPHealthcare$74.45B
4.73%
7REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
4.50%
8IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
2.84%
9BDX
BECTON DICKINSON & COHealthcare$43.58B
2.77%
10TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
2.37%
11VEEV
VEEVA SYSTEMS INCHealthcare$31.74B
2.01%
12BIIB
BIOGEN INCHealthcare$30.41B
1.93%
13INCY
INCYTE CORPHealthcare$23.42B
1.49%
14GH
GUARDANT HEALTH INCHealthcare$20.67B
1.31%
15VTRS
VIATRIS INCHealthcare$20.14B
1.28%
16JAZZ
JAZZ PHARMACEUTICALS PLCHealthcare$15.53B
0.99%
17DVA
DAVITA INCHealthcare$15.21B
0.97%
18ALGN
ALIGN TECHNOLOGY INCHealthcare$12.66B
0.80%
19BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
0.73%
20HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.59%
21IONS
IONIS PHARMACEUTICALS INCHealthcare$8.99B
0.57%
22TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.53%
23BIO
BIO-RAD LABORATORIES INCHealthcare$8.15B
0.52%
24LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.44%
25CHE
CHEMED CORPHealthcare$6.77B
0.43%
26XENE
XENON PHARMACEUTICALS INCHealthcare$6.60B
0.42%
27LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
0.39%
28TFX
TELEFLEX INCHealthcare$5.96B
0.38%
29BLCO
BAUSCH & LOMB CORPHealthcare$5.80B
0.37%
30TXG
10X GENOMICS INCHealthcare$5.55B
0.35%
31TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.33%
32SHC
SOTERA HEALTH COHealthcare$5.06B
0.32%
33VCYT
VERACYTE INCHealthcare$4.72B
0.30%
34VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
0.27%
35WAY
WAYSTAR HOLDING CORPHealthcare$4.27B
0.27%
36HAE
HAEMONETICS CORPHealthcare$3.54B
0.22%
37WRBY
WARBY PARKER INCHealthcare$3.24B
0.21%
38GRAL
GRAIL INCHealthcare$3.12B
0.20%
39VERA
VERA THERAPEUTICS INCHealthcare$2.76B
0.18%
40ESTA
ESTABLISHMENT LABS HOLDINGS INCHealthcare$2.72B
0.17%
41NEOG
NEOGEN CORPHealthcare$2.24B
0.14%
42IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
0.14%
43AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.13%
44HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.12%
45TYRA
TYRA BIOSCIENCES INCHealthcare$1.91B
0.12%
46NEO
NEOGENOMICS INCHealthcare$1.90B
0.12%
47MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.12%
48ZBIO
ZENAS BIOPHARMA INCHealthcare$1.86B
0.12%
49VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
0.12%
50ZYME
ZYMEWORKS INCHealthcare$1.77B
0.11%
51HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.11%
52BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.11%
53TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.11%
54INVA
INNOVIVA INCHealthcare$1.60B
0.10%
55VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.10%
56PRGO
PERRIGO CO PLCHealthcare$1.48B
0.09%
57ARDT
ARDENT HEALTH INCHealthcare$1.46B
0.09%
58XNCR
XENCOR INCHealthcare$1.30B
0.08%
59AZTA
AZENTA INCHealthcare$1.21B
0.08%
60TNDM
TANDEM DIABETES CARE INCHealthcare$1.17B
0.07%
61MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.07%
62WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.07%
63USPH
U S PHYSICAL THERAPY INCHealthcare$1.12B
0.07%
64EYPT
EYEPOINT INCHealthcare$1.12B
0.07%
65BVS
BIOVENTUS INCHealthcare$1.01B
0.06%
66VOR
VOR BIOPHARMA INCHealthcare$980M
0.06%
67PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.06%
68AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.06%
69AVR
ANTERIS TECHNOLOGIES GLOBAL CORPHealthcare$823M
0.05%
70ZVRA
ZEVRA THERAPEUTICS INCHealthcare$755M
0.05%
71TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.04%
72MYGN
MYRIAD GENETICS INCHealthcare$584M
0.04%
73WEAV
WEAVE COMMUNICATIONS INCHealthcare$575M
0.04%
74ANGO
ANGIODYNAMICS INCHealthcare$558M
0.04%
75ZURA
ZURA BIO LTDHealthcare$518M
0.03%
76XOMA
XOMA ROYALTY CORPHealthcare$504M
0.03%
77PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.03%
78UPB
UPSTREAM BIO INCHealthcare$382M
0.02%
79ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.02%
80ZSQR
Z SQUARED INCHealthcare$260M
0.02%
81SMTI
SANARA MEDTECH INCHealthcare$229M
0.01%
82KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.01%
83FOCL
FOCAL INCHealthcare$204M
0.01%
84AMWL
AMERICAN WELL CORPHealthcare$199M
0.01%
85TNXP
TONIX PHARMACEUTICALS HOLDING CORPHealthcare$198M
0.01%
86DERM
JOURNEY MEDICAL CORPHealthcare$197M
0.01%
87PDEX
PRO DEX INCHealthcare$183M
0.01%
88INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.01%
89INGN
INOGEN INCHealthcare$178M
0.01%
90RCEL
AVITA MEDICAL INCHealthcare$157M
0.01%
91UNCY
UNICYCIVE THERAPEUTICS INCHealthcare$144M
0.01%
92VTVT
VTV THERAPEUTICS INCHealthcare$130M
0.01%
93VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.01%
94AGPU
AXE COMPUTE INCHealthcare$72M
0.00%
95XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $1.58T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
26%6
48%13
18%11
1%9
1%11
1%5
<1%12
<1%10
<1%3

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 46% toward Growth. +4% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt98% → Large
SmallLarge
Value ↔ growth tilt46% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
5
Failed
1
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    64.5%
    Margin
    -10.5%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    24.6%
    Margin
    0.4%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.0 (95% CI 0.7-1.2)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
9.2%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
0.96x
within
parametric
0.95x
within
cornish fisher
0.83x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2002
Before publication (pre-2002)
0.27
Sharpe · 5.5% p.a.
January 1999December 2002 · 48 mo
Since publication
-0.09
Sharpe · -1.1% p.a.
January 2003July 2026 · 283 mo
Change in Sharpe−0.36the return reversed sign — the published edge now runs the other way

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
38%
10 of 26 3-year windows made money
Worst window
-0.96
Sharpe, January 2023 – December 2025
January 1999July 2026
Median Sharpe
-0.09
Dispersion
0.45
Best window
0.88

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.33.5%-2.2%
3 yearsp.a.7.6%-9.7%
5 yearsp.a.3.3%-4.2%
10 yearsp.a.9.9%-2.5%
Since inceptionp.a.10.0%-1.1%
Calendar years
YearLong legLong-short
20267 mo13.8%9.3%
202515.4%-15.1%
2024-3.9%-19.0%
2023-6.2%-15.8%
2022-3.2%26.7%
202125.0%-0.2%
202028.5%2.6%
201920.8%-4.0%
20181.0%-5.1%
201720.2%1.4%
20160.7%5.6%
201510.0%-0.3%
201419.5%-8.3%
201334.1%-18.9%
201214.8%2.4%
201116.9%28.4%
201010.5%0.6%
200927.0%2.0%
2008-22.0%-8.8%
2007-2.7%-11.2%
200610.2%2.3%
200513.7%3.7%
2004-0.8%-2.9%
200326.1%-3.9%
2002-19.7%-1.8%
2001-7.9%-2.0%
200058.4%-5.2%
19999.8%25.8%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCHH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-04-23 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$1.58T

Methodology

The Foundry Healthcare Inventory Discipline Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Inventory Discipline signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.